ConductScience.org, home

Comparison · NCT04168385-deaths

Maralixibat: ALGS vs Maralixibat: PFIC: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Maralixibat: ALGS vs Maralixibat: PFIC: deaths from any cause. Trial comparisons, record NCT04168385-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04168385-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.0250.004430.129wilson
Risk in group 200.00000000000000002780.242wilson
Risk difference, group 1 minus group 20.025-0.2180.129newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to harm, for one more death from any cause on Maralixibat: ALGS than on Maralixibat: PFIC40from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Maralixibat: ALGS
Participants will all receive Maralixibat oral solution~Maralixibat chloride oral solution orally twice daily Up to 1.2\* mg/kg/day), and according to indication.~\*equivalent to 1.14 mg/kg/day maralixibat. Doses reported here are in maralixibat chloride.~Participants with ALGS received maralixibat doses in the range of 0.15 mg/kg QD to 0.45 mg/kg BID.
140EG000
Group 2Maralixibat: PFIC
Participants will all receive Maralixibat oral solution~Maralixibat chloride oral solution orally twice daily Up to 1.2\* mg/kg/day), and according to indication.~\*equivalent to 1.14 mg/kg/day maralixibat. Doses reported here are in maralixibat chloride.~Participants with PFIC received maralixibat doses in the range of 0.3 mg/kg QD to 0.6 mg/kg BID.
012EG001

Harm

What it counts
Total, all-cause mortality
Time frame
The timeframe for reporting adverse events was from informed consent through approximately 4.5 years, including 30 days after last dose.

Source ClinicalTrials.gov

Trial

Title
MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study
NCT number
NCT04168385
Phases
PHASE2
Conditions
Cholestatic Liver Disease
Interventions
Maralixibat
Lead sponsor
Mirum Pharmaceuticals, Inc.
Results first posted
2025-12-08

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04168385-deaths